Navigation Links
Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
Date:12/5/2007

DANBURY, Conn., Dec. 5 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that it will issue its fourth quarter and fiscal year 2007 financial results on December 11, 2007. Following the issuance of its financial results, Biodel's senior management team will host a conference call to discuss the results.

December 11, 2007 Schedule:

After the market closes Q4 and fiscal year 2007 results will be

distributed by PR Newswire

4:20 p.m. EST To participate in the conference call, dial:

1-877-718-5104 (United States) or

1-719-325-4779 (International)

4:30 p.m. EST Conference call begins

Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at http://www.biodel.com. The audio webcast will be archived and available for replay 14 days following the event.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and two osteoporosis product candidates in pre-clinical studies. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.


'/>"/>
SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Aug. 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), ... technologies and products for advanced microarray diagnostics, today announced ... August 22 at 2:00 pm ET.  ... provide a brief review of SQI,s recent commercialization progress ... diagnostics industry veteran recently appointed to the Board of ...
(Date:8/18/2014)...   Sterne, Kessler, Goldstein & Fox P.L.L.C. , ... DC , announced today that it has filed ... with the U.S. Patent and Trademark Office (USPTO) on ... Inc. (Nasdaq: BRLI).  These IPR petitions aim to nullify ... Inc. These patents have been asserted against GeneDx in ...
(Date:8/18/2014)... (PRWEB) August 18, 2014 Global HIV ... pharma report announced by Reportstack. The rate of HIV infection ... on a declining note at a positive rate across the ... from 2.3 million in 2005 to 1.5 in 2013, with ... cause for such drastic changes in the infection rates has ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 10, 2011 Verenium Corporation (Nasdaq: VRNM ... development and commercialization of high-performance enzymes, today reported a ... the third quarter and nine months ended September 30, ... operational progress in the first nine months of this ...
... Science (Tianjin) Co. Ltd., a leading research-based contract manufacturer of ... sites in the U.S. and China, was pleased to receive ... and manufacturing facility on the afternoon of October 24th, 2011. ... Political Bureau of the CPC Central Committee and Premier of ...
... UV Flu Technologies, Inc. ( OTCBB: UVFT ... has expanded its International Distribution by adding representation in Oman, ... the Company,s Distributor in India, Ormed Systems, a leader in ... other parts of the world. The Company continues efforts in ...
Cached Biology Technology:Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 2Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 3Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 4Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 5Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 6Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 7Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 8Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011 9Premier Wen Visits Asymchem's Tianjin Facility 2UV Flu Technologies Expands Its International Footprint 2UV Flu Technologies Expands Its International Footprint 3
(Date:8/19/2014)... caesarean section rate, suggests a new commentary published today ... Obstetrics and Gynaecology (BJOG) . , China has one ... Of 16 million babies born in 2010, approximately half ... known, the current Chinese language literature on caesarean rates ... to 58%. However, before the 1980s, the caesarean rate ...
(Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome ... more difficult time going through withdrawal than others, ... While genetic and epigenetic (when genes are turned ... as potential factors, researchers at Boston University School ... conducted a first of its kind study to ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... this weeks PLoS Medicine, researchers have found that more ... infectious eye disease trachoma. Six million people most ... the developing world are blind because of the ... that multiple strains of the Chlamydiceae family of bacteria ...
... Hydrogen peroxide, the same mild acid that many people use ... also produced by the body to keep cells healthy. Now, ... how part of this complex process works. Reporting ... by W. Todd Lowther, Ph.D., developed a three-dimensional snapshot of ...
... coalition of 17 organizations, including the National Academy ... the National Science Teachers Association, is calling on ... the promotion of science education, including evolution. According ... issue of The FASEB Journal, the introduction of ...
Cached Biology News:Multiple species of bacteria may cause trachoma: Implications for treatment 2Research explores role of hydrogen peroxide in cell health 2Evolution education is a 'must' says coalition of scientific and teaching organizations 2
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Biology Products: